Aclidinium (Bromide)

Aclidinium Bromide (LAS 34273; LAS-W 330) is a long-acting, inhaled muscarinic antagonist. Aclidinium Bromide has the potential for chronic obstructive pulmonary disease (COPD) research[1][2][3][4].

Product Specifications

CAS Number

[320345-99-1]

Product Name Alternative

LAS 34273; LAS-W 330

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Aclidinium-Bromide.html

Purity

98.96

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

O=C(O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)C(C4=CC=CS4)(O)C5=CC=CS5.[Br-]

Molecular Formula

C26H30BrNO4S2

Molecular Weight

564.55

Precautions

H302, H315, H319, H335

References & Citations

[1]Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr Opin Investig Drugs. 2009 May;10 (5) :482-90.|[2]Joos GF. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2010 Feb;19 (2) :257-64.|[3]Sentellas S, Ramos I, Albertí J et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010 Mar 18;39 (5) :283-90.|[4]Sims MW, Panettieri RA Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:457-66.